John W. Clader

Statistics

Publications

Citations

3.9K

H-Index

Active since

1979

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Duke University

LabCorp (United States)

Cornell University

John W. Clader is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in pharmacology, medicinal chemistry, and drug discovery.

Publications per year

1979–2016

Publications

Discovery of 1-(4-Fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)- hydroxypropyl]-(4S)-(4-hydroxyphenyl)-2-azetidinone (SCH 58235): A Designed, Potent, Orally Active Inhibitor of Cholesterol Absorption

Stuart B. Rosenblum, Tram Huynh, Adriano Afonso et al. · Journal of Medicinal Chemistry · 1998 · 355 citations

Pharmacy, Medicinal Chemistry, Pharmacology +11

HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use

Alexandra Trkola, Shawn E. Kuhmann, Julie Strizki et al. · Proceedings of the National Academy of Sciences · 2002 · 304 citations · Full text

Life Sciences, Molecular Biology, Pharmacology +15

SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo

Julie Strizki, Serena Xu, Nicole Wagner et al. · Proceedings of the National Academy of Sciences · 2001 · 300 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +16

2-Azetidinones as Inhibitors of Cholesterol Absorption

Duane A. Burnett, Mary Ann Caplen, Harry R. Davis et al. · Journal of Medicinal Chemistry · 1994 · 239 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +5

Analysis of the Mechanism by Which the Small-Molecule CCR5 Antagonists SCH-351125 and SCH-350581 Inhibit Human Immunodeficiency Virus Type 1 Entry

Fotini Tsamis, Svetlana Gavrilov, Francis Kajumo et al. · Journal of Virology · 2003 · 204 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +17

1–5 of 71